NCT03487783View on ClinicalTrials.gov

Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Tourette's Syndrome

PHASE3CompletedINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

May 2, 2018

Primary Completion Date

February 14, 2020

Study Completion Date

February 14, 2020

Conditions
Tourette Syndrome
Interventions
DRUG

Aripiprazole Oral Solution

Aripiprazole 2-20 mg/day (2-20 mL/day)

DRUG

Placebo Oral Solution

Placebo 2-20 mg/day (2-20 mL/day)

Trial Locations (1)

100088

Beijing Anding Hospital of Capital Medical University, Beijing

Sponsors
All Listed Sponsors
lead

Otsuka Beijing Research Institute

INDUSTRY